Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal.

Mass administration of azithromycin to eliminate blindness due to trachoma has raised concerns regarding the emergence of antimicrobial resistance. During 2000, we compared the antimicrobial resistance of nasopharyngeal pneumococcal isolates recovered from and the prevalence of impetigo, respiratory symptoms, and diarrhea among 458 children in Nepal before and after mass administration of azithromycin. No azithromycin-resistant pneumococci were isolated except from 4.3% of children who had received azithromycin during 2 previous mass treatments (P<.001). There were decreases in the prevalence of impetigo (from 14% to 6% of subjects; adjusted odds ratio [OR], 0.41; 95% confidence interval [CI], 0.21-0.80) and diarrhea (from 32% to 11%; adjusted OR, 0.26; 95% CI, 0.14-0.43) 10 days after azithromycin treatment. The absence of macrolide-resistant isolates after 1 mass treatment with azithromycin is encouraging, although the recovery of azithromycin-resistant isolates after 2 mass treatments suggests the need for resistance monitoring when multiple rounds of antimicrobial treatment are given.

[1]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[2]  C. Whitty,et al.  Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. , 1999, The Pediatric infectious disease journal.

[3]  H. Gilles,et al.  The conquest of 'river blindness'. , 1991, Annals of tropical medicine and parasitology.

[4]  G. Johnson,et al.  Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. , 2000, Investigative ophthalmology & visual science.

[5]  H. Jha,et al.  Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. , 2001, Bulletin of the World Health Organization.

[6]  H. Whittle,et al.  Randomised controlled trial of single-dose azithromycin in treatment of trachoma , 1993, The Lancet.

[7]  K. Tabbara,et al.  Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. , 1996, Ophthalmology.

[8]  J. Mathews,et al.  A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  S. Block,et al.  Future indications for macrolides. , 1997, The Pediatric infectious disease journal.

[10]  Susan R. Johnson,et al.  Macrolide Resistance among Invasive Streptococcus Pneumoniae Isolates , 2022 .

[11]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .

[12]  M. Leinonen,et al.  Weekly oral azithromycin as prophylaxis for agents causing acute respiratory disease. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  R. Adegbola,et al.  Effect of azithromycin on pharyngeal microflora. , 1995, The Pediatric infectious disease journal.

[14]  R. J. Thomas,et al.  Penicillin prophylaxis for streptococcal infections in United States Navy and Marine Corps recruit camps, 1951-1985. , 1988, Reviews of infectious diseases.

[15]  P Huovinen,et al.  The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.

[16]  R. Rubinstein,et al.  A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Whitcher,et al.  Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area , 1999, The British journal of ophthalmology.

[18]  B. Greene,et al.  Community-based treatment of onchocerciasis with ivermectin: safety, efficacy, and acceptability of yearly treatment. , 1991, The Journal of infectious diseases.

[19]  M. Tarlow Laboratory, clinic and community: the logistics of liaison. , 1997, The Pediatric infectious disease journal.

[20]  A D Négrel,et al.  Global data on blindness. , 1995, Bulletin of the World Health Organization.

[21]  S. Cairncross,et al.  Review of the evidence base for the ‘F’ and ‘E’ components of the SAFE strategy for trachoma control , 2000, Tropical medicine & international health : TM & IH.

[22]  George M. Carlone,et al.  Evaluation of a Medium (STGG) for Transport and Optimal Recovery of Streptococcus pneumoniae from Nasopharyngeal Secretions Collected during Field Studies , 2001, Journal of Clinical Microbiology.

[23]  R. Wong,et al.  Acute infectious diarrhea. , 1993, The Medical clinics of North America.

[24]  T. Quinn,et al.  Azithromycin in control of trachoma , 1999, The Lancet.

[25]  T. Adam,et al.  Integrated management of the sick child. , 1995, Bulletin of the World Health Organization.

[26]  S. Schrag,et al.  Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. , 2000, Clinical microbiology reviews.

[27]  G. Burnham Adverse reactions to ivermectin treatment for onchocerciasis. Results of a placebo-controlled, double-blind trial in Malawi. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.